Cemiplimab

Cemiplimab, sold under the brand name Libtayo, is a monoclonal antibody medication for the treatment of squamous cell skin cancer.[5][6] Cemiplimab belongs to a class of drugs that binds to the programmed death receptor-1 (PD-1), blocking the PD-1/PD-L1 pathway.[4][7] The most common side effects include fatigue, rash, diarrhea, musculoskeletal pain, and nausea.[5][4] In September 2018, it was appr... [wikipedia]